Caged Glutamate Compounds
| Cat. No. | Product Name / Activity |
|---|---|
| 6553 | JF-NP-26 |
| Caged Raseglurant (Cat. No. 4416) | |
| 1490 | MNI-caged-L-glutamate |
| Stable photoreleaser of L-glutamate | |
| 3574 | RuBi-Glutamate |
| Caged glutamate; excited by visible wavelengths |
Literature for Caged Glutamate Compounds
Tocris offers the following scientific literature for Caged Glutamate Compounds to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Our Metabotropic Glutamate Receptor review gives an overview of the pharmacological ligands used to study the mGlu receptors.
Request copyRequest PDFWritten by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF